Renal Artery Stenosis

Renal Artery Stenosis (RAS) is the narrowing of one or both of the renal arteries, which supply blood to the kidneys. This restriction of blood flow can cause renovascular hypertension and ischemic nephropathy, potentially leading to chronic kidney disease and end-stage renal disease.

• Atherosclerosis (approx. 90% of cases): Plaque buildup primarily in older adults.
• Fibromuscular Dysplasia (FMD) (approx. 10% of cases): Abnormal cellular growth in artery walls, primarily affecting younger females.
• Rare Causes: Large-vessel vasculitis (e.g., Takayasu arteritis), neurofibromatosis type 1, thromboembolic disease, or extrinsic compression.

Narrowing of the renal artery lumen reduces renal perfusion pressure. This hypoperfusion stimulates the juxtaglomerular apparatus to secrete excess renin. Renin converts angiotensinogen to angiotensin I, which is converted to angiotensin II by Angiotensin-Converting Enzyme (ACE). Angiotensin II causes systemic vasoconstriction and stimulates aldosterone secretion, promoting sodium and water retention. Over time, persistent hypoperfusion leads to glomerular capillary collapse, tubulointerstitial fibrosis, and irreversible renal atrophy.

• Prevalence: Present in under 1% of patients with mild hypertension but up to 10-40% of patients with acute, severe, or refractory hypertension.
• Age/Gender: Atherosclerotic RAS is most common in males >50 years. FMD-associated RAS is most common in females aged 15–5

• Advanced age (>50 years)
• Tobacco smoking
• Diabetes mellitus
• Hyperlipidemia
• Coexisting peripheral artery disease (PAD) or coronary artery disease (CAD)

• Vitals: Severe systolic and diastolic hypertension.
• Auscultation: Systolic-diastolic abdominal bruit in the epigastrium or renal flanks (high specificity for RAS).
• Inspection/Palpation: Peripheral edema in advanced ischemic nephropathy.

• A. Clinical Assessment: Suspected in patients with sudden-onset or drug-resistant hypertension.
• B. Laboratory Testing: Assessment of renal function, electrolytes, and renin activity.
• C. Imaging Studies: Renal Duplex Ultrasound, Computed Tomography Angiography (CTA), Magnetic Resonance Angiography (MRA).
• D. Functional Tests: Renal scintigraphy (Captopril renal scan).
• E. Biopsy Findings: Rarely indicated; may show glomerular ischemic collapse and tubular atrophy.
• F. Genetic Testing: Not routinely indicated except in suspected neurofibromatosis or familial FMD.
• G. Differential Diagnosis: Essential hypertension, pheochromocytoma, primary aldosteronism.

Serum Creatinine
Type: Blood Test
Purpose: Evaluate baseline kidney function and detect ischemic nephropathy.
Expected Findings: Normal or elevated.
Interpretation: Elevation post-initiation of ACE inhibitors suggests bilateral RAS. Estimated Glomerular Filtration Rate (eGFR)
Type: Blood Test
Purpose: Stage chronic kidney disease secondary to RAS.
Expected Findings: Decreased eGFR (<60 mL/min/1.73 $m^2$).
Interpretation: Indicates severity of renal impairment. Plasma Renin Activity (PRA)
Type: Blood Test
Purpose: Assess RAAS activation.
Expected Findings: Elevated renin levels in unilateral RAS.
Interpretation: Confirms renin-dependent hypertension.

Renal Duplex Ultrasonography: Purpose: Initial non-invasive screening. Typical Findings: Peak systolic velocity (PSV) $>180\text{ cm/s}$ and renal-to-aortic ratio (RAR) $>3.5$. Clinical Importance: Highly operator-dependent but avoids radiation/nephrotoxic contrast.
Computed Tomography Angiography (CTA): Purpose: Visualize renal artery anatomy. Typical Findings: Visual narrowing/calcification of the renal artery lumen. Clinical Importance: High spatial resolution; requires iodinated contrast (caution in CKD).
Magnetic Resonance Angiography (MRA): Purpose: Evaluate renal vasculature without iodinated contrast. Typical Findings: High-definition narrowing of the renal artery. Clinical Importance: Avoids ionizing radiation; gadolinium contrast carries risk of Nephrogenic Systemic Fibrosis in severe renal failure.
Renal Arteriography (Gold Standard): Purpose: Definitive diagnosis and potential intervention. Typical Findings: "String of beads" appearance (FMD) or proximal focal stenosis (atherosclerosis). Clinical Importance: Invasive; reserved for patients undergoing concurrent revascularization.

• Essential Hypertension: Lacks abdominal bruits; blood pressure is usually responsive to standard dual-therapy.
• Primary Aldosteronism: Characterized by low plasma renin levels and elevated aldosterone-to-renin ratio.
• Pheochromocytoma: Accompanied by episodic palpitations, diaphoresis, and elevated plasma free metanephrines.

• End-stage renal disease (ESRD)
• Congestive heart failure (CHF)
• Myocardial infarction (MI) and ischemic stroke
• Aortic dissection

• FMD: Excellent prognosis; high cure or improvement rate of hypertension after angioplasty.
• Atherosclerotic RAS: Progressive disease. Medical therapy and lifestyle adjustments significantly reduce cardiovascular mortality, but long-term renal function depends on the degree of ischemic damage already present.

• Primary: Control of cardiovascular risk factors (lipid management, diabetes control, smoking avoidance).
• Secondary: Regular monitoring of renal function and blood pressure in patients diagnosed with subclinical atherosclerosis.

The following homeopathic remedies have been historically indicated for symptoms associated with Renal Artery Stenosis. Selection should be based on individualized symptom totality and constitutional assessment.

• Homeopathy by Hadhrat Mirza Tahir Ahmad (r.a.) — Primary clinical reference
• Robin Murphy — Lotus Materia Medica (3rd Edition)
• William Boericke — Pocket Manual of Homœopathic Materia Medica & Repertory
• ICD-10/ICD-11 Classification — World Health Organization
• Harrison's Principles of Internal Medicine (Reference Standard)

This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.

📊 Advanced Kidney & Renal Function Analyzer

Comprehensive nephrology panel. Calculates eGFR (CKD-EPI 2021 formula), CKD Stage, BUN/Creatinine Ratio, and Creatinine Clearance (Cockcroft-Gault) from a single lab panel.